BCB Bancorp Takes the Bath — and Asks the Market to Believe the Ending
A $200M loan sale, a $60M DTA write-off, and a completed capital raise reset the story; the flat tape says investors want proof, not adjectives.
BCBP · Earnings Call · 2026-10-29
The quarter that was supposed to end the story
BCB Bancorp’s third quarter was not a normal earnings event; it was a balance-sheet reset. The company sold more than $200 million of mostly criticized and classified loans, marked another $100 million to fair value, took a $60 million valuation allowance against its deferred tax asset, and completed a capital raise. Tom O’Brien, who joined June 1, opened with the line of a CEO who wants credit for a very painful to-do list: “Never quite reported a quarter like this in my career... we successfully accomplished everything that was set out on my June 1st call when I joined the bank, and actually more than that.” — Thomas O'Brien, CEO · 2026-10-29
The quarter’s own keyword deck reads like a triage log: asset quality, classified loans, reserve coverage, valuation allowance, criticized loans, loan sales, and capital raise. This is not a growth story. It is a cleanup story.
Operationally, the cleanup landed. Classified loans fell from $160 million to $46 million, a 70% reduction, while reserve coverage on that bucket rose from 28% to 150%, according to CFO Jawad Chaudhry. Criticized loans dropped from $207 million to $153 million. Nonperforming loans are down to $22 million, and the allowance for credit losses starts Q4 at $70 million, over 3% of loans. The company also downgraded another $77 million of previously pass-rated loans to special mention or substandard, which is the kind of thing management does when it wants to stop being surprised. Two larger problem loans were paid in full during the quarter.
O’Brien insisted the review was exhaustive:
I do not know what else we could have done to identify and price the credits that we have concern of potential loss in.
What changed — and what didn’t
Two prior-call tensions resolved. In August, O’Brien was asked about a capital raise and said “I just don't know. And as I said, it's complicated by the holding company structure, too.” — Thomas O'Brien, President and CEO · 2026-08-03 This quarter, the capital raise is done, and the holding company — the top keyword last quarter — has vanished from the current top-30 deck. That may mean the capital raise addressed the double-leverage problem. Or it may mean management is not ready to discuss the remaining holding-company debt and preferred stock. The call does not say.
DTA is different. In August, asked whether a valuation reserve might be needed, O’Brien said “We do not believe we're going to be in that position. We think once we're done with this process, the DTA will get utilized actually pretty efficiently.” — Thomas O'Brien, President and CEO · 2026-08-03 Three months later, BCB took a 100% valuation allowance against the deferred tax asset — $60 million. That is a reversal, not a nuance. O’Brien now calls the recapture “kind of binary... by the end of 2027, assuming both quantity and quality of earnings in each of the next five quarters support the decision” — Thomas O'Brien, CEO · 2026-10-29. Investors should treat the DTA as an option on five clean quarters, not as a near-term earnings asset.
The credit review also followed through on last quarter’s promise. In August, O’Brien said on commercial real estate that “the vast majority continue to be reviewed. Some of the larger ones have been done already, but the vast majority, we still have more analytics to go through.” — Thomas O'Brien, President and CEO · 2026-08-03 The Q3 deep dive covered every loan over $1 million; the $77 million of downgrades is the output. The acute Business Express loan problem is fading: the portfolio is about $65 million, Q3 losses were close to $1 million, and reserve coverage rose from 15% to 18%. “The Business Express loan portfolio balance is approximately $65 million now. The portfolio continues to behave well.” — Jawad Chaudhry, CFO · 2026-10-29 That is a real improvement from the prior call’s language about a portfolio that had been “the source of a lot of loss.”
The loose end is cannabis. The cannabis loans were marked to market at September 30, and management still expects to sell the remaining portfolio in Q4: “about $70 million to $80 million in deposits and about $70 million in loans... pretty far along” — Thomas O'Brien, CEO · 2026-10-29. A $70 million loan book plus $70-80 million of deposits is material for a $149 million market-cap bank. If the deal slips, the cleanup timeline slips with it.
The tape’s verdict
The numbers are not yet in the filed financials — the latest 10-Q still covers the June quarter, when BCB reported a $15 million net loss and an efficiency ratio of 55.3%. The Q3 GAAP figures will be dominated by the loan-sale losses, the $100 million fair-value write-down, and the $60 million DTA charge. That is why O’Brien waved off the income statement as “telephone book numbers.” The relevant forward number is not EPS; it is whether the $70 million ACL and the remaining $153 million of criticized loans are enough.
Deposits were already shrinking before the cannabis exit: $2.6 billion at the last filing, down 1% year over year. Management says the one sector-wide lever that helped was cost of deposits, which trended lower and supported the 3.03% net interest margin. But the global regional-bank conversation is about deposit competition and funding costs; BCB’s conversation is about whether the residual loan book is clean. That makes this a company-specific credit event, not a sector read-through.
The market’s reaction is the tell. BCB’s stock is not acting like a cleared-out turnaround: the tape shows a 2.2% decline over the 60 trading days to October 29, a flat line with a $9.00 peak on August 13 and a 4.3% drawdown from that high. The deck tags it as a capital issuance; O’Brien calls the raise “very successful” and says the stock “has reacted favorably since.” The tape says the market is still in show-me mode.
The quarter is a genuine inflection attempt: capital raised, risk ratings scrubbed, problem loans sold, DTA written down, cannabis exit teed up. But the proof points are all forward. BCB needs a clean Q4, a closed cannabis sale, no new downgrades, and five quarters of earnings to recapture the DTA. If that happens, the flat tape is an opportunity. If it does not, the $100 million write-down and the $60 million valuation allowance are a reminder that this bank’s legacy problems have been expensive to discover. The market is not yet paying for the ending.